0.2436 -0.013 (-5.18%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.47 | 1-year : | 0.63 |
Resists | First : | 0.4 | Second : | 0.54 |
Pivot price | 0.26 | |||
Supports | First : | 0.19 | Second : | 0.16 |
MAs | MA(5) : | 0.25 | MA(20) : | 0.25 |
MA(100) : | 0.26 | MA(250) : | 0.57 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 11.9 | D(3) : | 12.2 |
RSI | RSI(14): 48.3 | |||
52-week | High : | 1.8 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BGXX ] has closed above bottom band by 31.4%. Bollinger Bands are 2.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.26 - 0.26 | 0.26 - 0.26 |
Low: | 0.24 - 0.24 | 0.24 - 0.24 |
Close: | 0.24 - 0.24 | 0.24 - 0.25 |
Bright Green Corporation grows, manufactures, and sells cannabis and cannabis-related products legally under federal and state laws for research, pharmaceutical applications, and export. The company was incorporated in 2019 and is based in Fort Lauderdale, Florida.
Fri, 15 Mar 2024
US cannabis firm Bright Green plans 102-MW solar field in New Mexico - Renewables Now
Fri, 15 Mar 2024
Bright Green Corp. plans $250M expansion to Grants drug research, production facility - Albuquerque Business First - The Business Journals
Thu, 14 Mar 2024
Bright Green to install 102-megawatt solar power generation field (NASDAQ:BGXX) - Seeking Alpha
Tue, 12 Mar 2024
Bright Green to expand New Mexico facility with $250 million project By Investing.com - Investing.com
Tue, 12 Mar 2024
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF - GlobeNewswire
Mon, 11 Mar 2024
Bright Green Corp Enhances Leadership and Governance - TipRanks.com - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 184 (M) |
Shares Float | 64 (M) |
Held by Insiders | 62.6 (%) |
Held by Institutions | 9.3 (%) |
Shares Short | 2,790 (K) |
Shares Short P.Month | 2,320 (K) |
EPS | -0.06 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.09 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -26.7 % |
Return on Equity (ttm) | -66.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.05 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -1 (M) |
PE Ratio | -4.88 |
PEG Ratio | 0 |
Price to Book value | 2.7 |
Price to Sales | 0 |
Price to Cash Flow | -113.19 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |